Perrigo Company, a leading global provider of quality, affordable healthcare products, has started shipments of Guaifenesin 600mg extended-release tablets in a launch to its retail and wholesale customers. This major new product is the first product that is generically equivalent to Mucinex 600mg extended release tablets.
The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg extended-release tablets.
Mucinex 600mg extended-release tablets (Guaifenesin 600mg extended-release tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $135 million through food, drug and mass merchandisers for the last 12 months.
Perrigo's chairman and CEO Joseph C Papa stated, "This launch is representative of the Perrigo team's abilities to overcome challenging circumstances as evidenced by this product's complex formulation and patent challenges. The team worked diligently to formulate the product, prove the product's non-infringement to existing patents, validate and achieve commercial production, and bring the product to market. Perrigo's achievement represents the first store brand equivalent to be approved by the US Food and Drug Administration and marketed to consumers as a high quality store brand product that will represent considerable savings when compared to the national brand. This is another excellent example of Perrigo's investment and commitment to making quality healthcare more affordable for our customers."
Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. The company develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, pet health, dietary supplements and active pharmaceutical ingredients (API).